| 穆金兴,李雪霞,李延鑫,等.比伐卢定对行经皮冠状动脉介入治疗病人疗效及心肌梗死溶栓试验、心肌灌注评分、心脏主要不良事件的影响分析[J].安徽医药,2019,23(4):700-702. |
| 比伐卢定对行经皮冠状动脉介入治疗病人疗效及心肌梗死溶栓试验、心肌灌注评分、心脏主要不良事件的影响分析 |
| Effect of bivalirudin on patients with percutaneous coronary intervention and myocardial infarction thrombolysis, myocardial perfusion grade, and major adverse cardiac events |
| 投稿时间：2017-09-11 |
| DOI： |
| 中文关键词: 急性冠状动脉综合征 心肌灌注显像 白细胞介素6 C反应蛋白质 经皮冠状动脉介入治疗 比伐卢定 心脏主要不良事件 心肌梗死溶栓试验 心肌灌注评分 |
| 英文关键词: Acute coronary syndrome Myocardial perfusion imaging Interleukin-6 C-reactive protein Percutaneous coronary intervention Bivalirudin Major adverse cardiac events Thrombolytic inhibition in myocardial infarction TIMI myocardial perfusion grade |
| 基金项目: |
|
| 摘要点击次数: 1836 |
| 全文下载次数: 600 |
| 中文摘要: |
| 目的 研究比伐卢定对行经皮冠状动脉介入治疗(PCI)病人疗效及心肌梗死溶栓试验(TIMI)、心肌灌注评分(TMPG)、心脏主要不良事件(MACE)的影响。方法 选取2015年2月至2016年3月于邢台市第三医院接受PCI治疗的病人100例,采用随机数字表法分成观察组与对照组,每组50例。对照组病人在PCI术后予以普通肝素治疗,观察组病人则在PCI术后予以比伐卢定治疗。对两组病人均进行为期30 d的随访,比较两组治疗后TIMIⅢ级发生率、TMPG≥Ⅱ级发生率,治疗30 d后MACE发生情况与再出血情况,治疗前后血清白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平变化情况。结果 观察组TIMIⅢ级发生率、TMPG≥Ⅱ级发生率分别为94.00%(47/50)、90.00%(45/50),均明显高于对照组的80.00%(40/50)、74.00%(37/50),均差异有统计学意义(均P＜0.05)。治疗30 d后观察组病人MACE发生率为4.00%(2/50),明显低于对照组的16.00%(8/50),差异有统计学意义(P＜0.05)。观察组出血事件发生率为6.00%(3/50),明显低于对照组的20.00%(10/50),差异有统计学意义(P＜0.05)。治疗后观察组病人血清IL-6、hs-CRP水平分别为(23.5±3.7)U/L、(17.5±3.4)mg/L,均明显低于对照组的(31.6±4.2)U/L、(25.9±3.0)mg/L,均差异有统计学意义(均P＜0.05)。结论 比伐卢定治疗经PCI治疗病人的效果明显,有利于降低MACE与再出血事件发生率,同时有效减轻炎症反应。 |
| 英文摘要: |
| Objective To study the curative effect of bivalirudin on percutaneous coronary intervention (PCI) patients and the effects of bivalirudin on thrombolytic inhibition in myocardial infarction (TIMI),TIMI myocardial perfusion grade (TMPG),and major adverse cardiac events (MACE).Methods A hundred patients,who underwent PCI in Xingtai Third Hospital from February 2015 to March 2016 were enrolled and assigned into observation group (n=50) and control group (n=50) by random number table method.Patients in the control group were given unfractionated heparin treatment after PCI,while patients in the observation group were given bivalirudin after PCI.The patients in both groups were followed up for 30 days.The incidences of TIMI Ⅲ and TMPG≥Ⅱ,the incidence of MACE and rebleeding after 30 days of treatment,changes in serum interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) levels before and after treatment were compared between the two groups.Results The incidences of TIMI grade Ⅲ and TMPG≥Ⅱ in the observation group were 94.00% (47/50) and 90.00% (45/50),respectively,which were significantly higher than the control group's 80.00% (40/50) and 74.00% (37/50);the differences were statistically significant (both P<0.05).After 30 days of treatment,the incidence of MACE in the observation group was 4.00% (2/50),which was significantly lower than that in the control group (16.00%,8/50);the difference was statistically significant (P<0.05).The incidence of bleeding events in the observation group was 6.00% (3/50),which was significantly lower than that in the control group (20.00%,10/50);the difference was statistically significant (P<0.05).The levels of serum IL-6 and hs-CRP in the observation group were (23.5±3.7) U/L and (17.5±3.4) mg/L,respectively,which were significantly lower than those in the control group [(31.6±4.2) U/L,(25.9±3.0) mg/L,respectively];the differences were statistically significant (both P<0.05).Conclusion The curative effect of bivalirudin on PCI patients is obvious,which can reduce the incidences of MACE and rebleeding,and effectively reduce the inflammatory reaction. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
